Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy

Cancer immunotherapy has significantly advanced the treatment paradigm in oncology, with approvals of immuno‐oncology agents for over 16 indications, many of them first line. Checkpoint inhibitors (CPIs) are recognized as an essential backbone for a successful anticancer therapy regimen. This review...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasichayanula, Sreeneeranj, Mandlekar, Sandhya, Shivva, Vittal, Patel, Maulik, Girish, Sandhya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372426/
https://www.ncbi.nlm.nih.gov/pubmed/35588531
http://dx.doi.org/10.1111/cts.13312

Ejemplares similares

Ejemplares similares